• Deepcell

  Participated · Series B · Mar 2022

  Deepcell has built a platform that combines deep learning, proprietary microfluidics, high‑resolution optics and a growing cell atlas of over 1 billion images to analyze and sort single cells based on visual features. The technology isolates and collects label‑free single cells by morphology while maintaining cell viability for downstream biological characterization. By analyzing whole, unperturbed single cells rather than molecular targets, Deepcell aims to reveal cellular heterogeneity and connect morphology to multi‑omics. The company plans to continue product development, expand the team, transition to late‑stage development, and enable early commercial introduction of its platform as a service for translational research, diagnostics and therapeutic development. Financially, Deepcell closed a $73 million Series B and has raised nearly $100 million in total funding since its 2017 founding. Deepcell develops an AI-powered platform that classifies and isolates individual cells by combining deep learning, microfluidics-based cell capture, and single-cell analysis. The platform sorts cells based on detailed visual features while maintaining cell viability for downstream single-cell workflows. It can isolate virtually any cell type, including extremely rare cells occurring at frequencies as low as one in a billion, and the company is building a cell morphology atlas of more than 400 million cells. Spun out of Stanford University in 2017 by co-founder and CEO Maddison Masaeli and co-founder Euan Ashley, Deepcell aims to enable hypothesis-free approaches to cell classification and sorting. The company is based in Mountain View, California. Financially, Deepcell closed a $20M Series A round led by Bow Capital with participation from Andreessen Horowitz, 50Y, DCVC, Stanford University and angel investors including Jeff Dean. Proceeds will fund development of its microfluidics-based technology and continued expansion of its cell atlas to advance translational research and precision medicine applications.

• OrthoSensor

  Led · Series C · Mar 2015

  OrthoSensor develops VERASENSE™, a disposable sensor-assisted instrument for total knee replacement that wirelessly delivers intraoperative data to guide ligament and implant positioning. The device enables surgeons to make evidence-based decisions on soft tissue balance and implant position in real time. The company is led by President and CEO Ivan Delevic. OrthoSensor raised new financing to support commercialization of VERASENSE and to expand product development activities. The funding round reflects the company’s effort to advance its core product toward broader market adoption. The company is based in Dania Beach, Florida. OrthoSensor develops and commercializes intelligent orthopaedic devices and data services. The company is led by President and CEO Jay Pierce and has developed the VERASENSE Knee System, an intelligent single-use device that provides surgeons with real-time, quantifiable data on implant placement, soft tissue balance and limb alignment. OrthoSensor closed a Series B-2 financing round that brought the total raised in the round to more than $48M. Series B investors included Dignity Health, Ziegler Meditech Equity Partners and undisclosed strategic and angel investors. The company intends to use the funds to grow the VERASENSE product line and to execute R&D, marketing and sales initiatives. OrthoSensor is based in Dania Beach, Florida. OrthoSensor develops and commercializes intelligent orthopedic devices across three product platforms: OrthoSensor Surgical, OrthoSensor Implantables and OrthoSensor Analytics. Its first product, the OrthoSensor™ Knee Balancer, is embedded with sensors that provide surgeons with actionable data on implant fit and knee kinematics to ensure proper soft tissue balance during total knee arthroplasty. The company plans to expand commercialization of the Knee Balancer and to launch a line of additional intelligent orthopedic devices. OrthoSensor closed an additional $15M in Series B financing, bringing the total Series B to $36M. The funding is intended to support commercialization and product launches. The company is led by CEO Jay Pierce and is based in Sunrise, Florida. OrthoSensor develops intelligent orthopedic devices and sensor-assisted surgery systems that provide surgeons with real-time, actionable information about implant placement and performance. Its technology targets knee, hip and shoulder replacement procedures as well as spinal and trauma applications. The company markets product lines named OrthoSensor Surgical, OrthoSensor Implantables and OrthoSensor Analytics. CEO Jay Pierce stated the company intends to use the new funding to move into the commercialization phase for these products. The company completed a $21M Series B financing to support that commercialization push. No operating metrics were disclosed in the article.

No current team members are available.